Trial Profile

A phase 2b/3, study of RLF-100 (aviptadil) to treat COVID-19 patients in Europe

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 18 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aviptadil (Primary)
Indications SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use

Most Recent Events

05 Nov 2021 According to a NRx Pharmaceuticals media release, the company is in the process of finalizing trial sites.
05 Apr 2021 According to RELIEF THERAPEUTICS Holding media release, company expects to initiate this trial in Europe later this year.
05 Apr 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com